Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
Status:
Completed
Trial end date:
2015-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the combination of one standard treatment for lung
cancer plus an additional drug, hydroxychloroquine. The standard treatment for lung cancer
being used includes 2 chemotherapy drugs, called paclitaxel and carboplatin. Some patients
who have a specific type of lung cancer can also receive another drug, a drug that targets
blood vessels, called bevacizumab (also known as avastin). Hydroxychloroquine is an FDA
approved drug for the treatment of malaria, rheumatoid arthritis and lupus erythematosis.
Phase:
Phase 2
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborators:
National Cancer Institute (NCI) Rutgers Cancer Institute of New Jersey